Tenaya Therapeutics Inc is expected to report a Q2 2026 consensus loss of $0.08 per share on revenue of $10.0 million, with its current stock price of $0.75 trading significantly below the average analyst price target of $10.20.
The primary focus for investors this quarter is the anticipated clinical data updates for lead gene therapy programs TN-201 and TN-401.
These programs target MYBPC3-associated hypertrophic cardiomyopathy and PKP2-associated arrhythmogenic right ventricular cardiomyopathy, respectively. Following encouraging initial readouts in late 2025, analysts are watching for longer-term efficacy and safety data to clarify registrational paths for these genetic heart disease therapies.